Apixaban

From Self-sufficiency
Jump to: navigation, search
Apixaban
File:Apixaban.png
Systematic (IUPAC) name
1-(4-methoxyphenyl)-7-oxo-6-[4-
(2-oxopiperidin-1-yl)phenyl]-4,5-
dihydropyrazolo[5,4-c]pyridine-
3-carboxamide
Clinical data
Routes of
administration
oral
Identifiers
CAS Number 503612-47-3
ATC code none
PubChem CID 10182969
ChemSpider 8358471
Chemical data
Formula C25H25N5O4
Molar mass 459.497[[Script error: No such module "String".]]
Script error: No such module "collapsible list".
Script error: No such module "TemplatePar".Expression error: Unexpected < operator.

Apixaban (manufacturer's designation BMS-562247-01) is a compound being investigated as an anticoagulant. It acts by inhibiting coagulation factor Xa. It is presently undergoing phase III trials in the prevention of venous thromboembolism, together with a number of related competing compounds, such as rivaroxaban.[1] It is being marketed in a joint venture by Pfizer and Bristol-Myers Squibb.[2]

A 2007 trial showed that apixaban was equivalent to enoxaparin/open-label heparin in preventing thrombosis in patients who had undergone a knee replacement.[3]

References

  1. Turpie AG (2007). "Oral, direct factor Xa inhibitors in development for the prevention and treatment of thromboembolic diseases". Arterioscler. Thromb. Vasc. Biol. 27 (6): 1238–47. doi:10.1161/ATVBAHA.107.139402. PMID 17379841. 
  2. "Bristol-Myers Squibb News Release 26 April 2007". Retrieved 2007-09-15. 
  3. Lassen MR, Davidson BL, Gallus A, Pineo G, Ansell J, Deitchman D (2007). "The efficacy and safety of apixaban, an oral, direct factor Xa inhibitor, as thromboprophylaxis in patients following total knee replacement". J. Thromb. Haemost. 5 (12): 2368–75. doi:10.1111/j.1538-7836.2007.02764.x. PMID 17868430. 


de:Apixaban

pt:Apixaban